Press Releases
November 19, 2019
TFF Pharmaceuticals Selects LaVoieHealthScience as Investor Relations and Corporate Communications Partner
TFF Pharmaceuticals to Ring NASDAQ Stock Market Opening Bell on Wednesday, November 20, 2019November 18, 2019
TFF Pharmaceuticals to Ring NASDAQ Stock Market Opening Bell on Wednesday, November 20, 2019
TFF Pharmaceuticals Prices $22 Million Public Offering of Common StockOctober 24, 2019
TFF Pharmaceuticals Prices $22 Million Public Offering of Common Stock
TFF Pharmaceuticals Raises $8.17 Million and Expands Leadership Team with New CFO and Director AppointmentsMay 30, 2019
TFF Pharmaceuticals Raises $8.17 Million and Expands Leadership Team with New CFO and Director Appointments
TFF Pharmaceuticals Receives Notice of Intention to Grant European Patent for Its Thin Film Freezing Process, Providing IP Protection in Europe until 2028September 27, 2018
TFF Pharmaceuticals Receives Notice of Intention to Grant European Patent for Its Thin Film Freezing Process, Providing IP Protection in Europe until 2028
TFF Pharmaceuticals Receives Notice of Allowance for New Foundational Patent Broadly Covering Novel Inhaled Dry Powder Drug Delivery PlatformJuly 11, 2018
TFF Pharmaceuticals Receives Notice of Allowance for New Foundational Patent Broadly Covering Novel Inhaled Dry Powder Drug Delivery Platform
TFF Pharmaceuticals Announces Appointment of Glenn Mattes as New Chief Executive OfficerMay 8, 2018
TFF Pharmaceuticals Announces Appointment of Glenn Mattes as New Chief Executive Officer
Biopharm Startup TFF Pharmaceuticals Raises $14M for Breakthrough Dry Powder Inhalation PlatformMay 3, 2018
Biopharm Startup TFF Pharmaceuticals Raises $14M for Breakthrough Dry Powder Inhalation Platform